Mary R. Grealy
President
Healthcare Leadership Council

Mary R. Grealy is president of the Healthcare Leadership Council, a coalition of chief executives of the nation’s leading healthcare companies and organizations. HLC advocates consumer-centered healthcare reform, emphasizing the value of private sector innovation. It is the only health policy advocacy group that represents all sectors of the healthcare industry. She was appointed to the position in August 1999. Ms. Grealy has an extensive background in healthcare policy. She has led important initiatives on the uninsured, improving patient safety and quality, protecting the privacy of patient medical information, and reforming the medical liability laws. She testifies regularly before Congress and federal regulatory agencies. She is a frequent public speaker on health issues and has been ranked many times by Modern Healthcare as one of the 100 Most Powerful People in Healthcare and has been named to Modern Healthcare’s list of the Top 25 Women in Healthcare for 2009.

Robert Ratner, M.D.
Chief Scientific & Medical Officer
American Diabetes Association (ADA)

Robert E. Ratner, M.D. is Chief Scientific & Medical Officer for the American Diabetes Association, the nation’s largest voluntary health organization leading the fight to Stop Diabetes®. Dr. Ratner provides leadership and oversight of scientific and medical activities including research, clinical affairs, program recognition and certification, medical information and professional education. In this capacity, he oversees the Association's support of a broad range of professional education activities and the development of the American Diabetes Association Clinical Practice Recommendations, clinical consensus reports and expert opinions. In 2012, the Association provided $34.6 million in research funds, funding more than 400 grants at 139 leading U.S. research institutions. Prior to joining the American Diabetes Association, Dr. Ratner was a Professor of Medicine at Georgetown University Medical School and Senior Research Scientist at the MedStar Health Research Institute in metropolitan Washington, DC. He completed a sabbatical as a Robert Wood Johnson Foundation Health Policy Fellow 2008-09, having served as the study director for the Institute of Medicine Comparative Effectiveness Research Priorities Committee, and a program examiner for health reform in the Health Division of the U.S. Office of Management and Budget. He received his MD from Baylor College of Medicine in Houston, Texas where he also completed his Internal Medicine training. He underwent fellowship training in Endocrinology and Metabolism at Harvard Medical School and the Joslin Diabetes Center in Boston.
Steven Griffen, M.D.
Vice President, Translational Development
JDRF

Steven C. Griffen, M.D., heads the Translational Development group, focusing on taking identified potential interventions into the clinic to establish their validity in early phase human clinical trials. These efforts move novel therapeutic innovations, both drugs and devices, into the clinic and ultimately into the hands of patients with T1D. Previously, Dr. Griffen served as leader of the AstraZeneca/Bristol Myers Squibb Alliance Type 1 Diabetes Development team. Prior to this role, Steve was a member of the Discovery Medicine and Clinical Pharmacology Department at Bristol-Myers Squibb where he led a Diabetes Exploratory Development team, bringing novel treatments from preclinical evaluation into the clinic for first in human studies through proof of concept. An endocrinologist by training, Dr. Griffen received his M.D. from the Medical College of Wisconsin, completed his residency training in Internal Medicine at the University of Michigan and his endocrinology fellowship at the University of California at San Francisco. Before his move to industry, Dr. Griffen was a faculty member at the University of California, Davis where he served as the Endocrine Fellowship Program Director and co-founded the Young Adult Diabetes Clinic, which focused on optimizing care for patients with type 1 diabetes. At the University of California, Davis, he also conducted a basic research program evaluating nutrient regulation of insulin gene expression in beta cells.

Samuel Stolpe, PharmD
Senior Director, Quality Strategies and Business Development
Pharmacy Quality Alliance (PQA)

Samuel F. Stolpe, PharmD is the Senior Director of Quality Strategies at the Pharmacy Quality Alliance (PQA), a quality organization that develops scientific methods of measuring safe and appropriate medication use for large patient populations. Sam has a multifaceted role at PQA, including responsibility for directing PQA’s research projects and educational initiatives. Sam’s most recent work has been focused on innovations in immunization delivery, the adherence impact of medication synchronization, and the use of motivational interviewing techniques by pharmacists. Sam leads PQA’s efforts in capturing the voice of the patient in PQA’s measurement development process through PQA’s Patient Advisory Panel. He also serves as the PQA staff liaison to the PQA Adult Immunization Task Force. Sam’s work on PQA educational initiatives includes oversight of the Academic Affairs Committee, the PQA Ambassador Program, and the award-winning Educating Pharmacists in Quality (EPIQ) CE training program. Sam directs both the PQA Fellowship Program, and the PQA APPE program for fourth year PharmD students. Sam has practiced in a variety of healthcare settings, coming to PQA in 2012 after completing a fellowship at the NACDS Foundation. Sam continues to practice as a community pharmacist, holds an adjunct faculty position at Howard University, and is currently pursuing graduate studies in epidemiology at the Harvard School of Public Health.